- 3 major US insurers (Aetna, Humana, and UnitedHealthcare) have inconsistent prior authorization policies for common medical services.
- Doctors spend an estimated 13 hours per week on prior authorization tasks, slowing down care.
- Insurers apply different rules for medical procedures, even for identical treatments.
- Prior authorization rules vary across insurers, including requirements for evidence and decision timelines.
- Administrative hurdles may hinder care quality and increase clinician workload.
Why do doctors need to fill out different forms, meet varying criteria, and wait different lengths of time just to get the same treatment approved for patients with similar insurance types? A growing body of evidence suggests that the answer lies in the fragmented and often arbitrary nature of prior authorization policies across major commercial health insurers. A recent brief research report published in Annals of Internal Medicine examined the prior authorization requirements of three of the largest U.S. insurers—Aetna, Humana, and UnitedHealthcare—and found striking inconsistencies in how and when they require pre-approval for common medical services. With clinicians spending an estimated 13 hours per week on prior authorization tasks, many are asking whether these administrative hurdles actually improve care or simply slow it down.
Do Major Insurers Use the Same Criteria for Prior Authorization?
The short answer is no. The Annals of Internal Medicine review revealed that even for identical medical procedures—such as MRI scans, biologics for autoimmune conditions, or certain cancer therapies—Aetna, Humana, and UnitedHealthcare applied vastly different rules for when prior authorization is required, what evidence must be submitted, and how quickly decisions are rendered. For example, one insurer might require prior auth for a routine lumbar MRI in patients without red flags, while another does not. In some cases, the same drug for rheumatoid arthritis was subject to prior authorization by two insurers but not the third. These discrepancies suggest a lack of standardized clinical guidelines across payers, leading to a patchwork system that depends more on insurance affiliation than medical necessity. This inconsistency forces providers to maintain multiple workflows and increases the risk of treatment delays.
What Evidence Supports the Claim of Inconsistency?
Researchers analyzed publicly available prior authorization policies from the three insurers as of 2023, focusing on 15 common procedures and medications across cardiology, orthopedics, dermatology, and rheumatology. They found that agreement on whether prior authorization was required occurred in less than 40% of cases. For instance, while UnitedHealthcare mandated pre-approval for CT angiography in stable chest pain patients, Aetna did not, and Humana’s policy varied by region. Similarly, dupilumab, a biologic used for severe eczema, required prior authorization from both Aetna and Humana but was automatically covered under certain UnitedHealthcare plans. According to the study, the average time to receive a decision ranged from 3 to 14 business days, with no clear correlation to clinical urgency. As Dr. Karen E. Joynt and colleagues noted in an accompanying editorial, “the current system is more reflective of insurer-specific bureaucracy than evidence-based medicine”.
Are There Arguments in Favor of Variable Prior Authorization Rules?
Some health policy experts argue that flexibility in prior authorization allows insurers to tailor coverage based on regional practice patterns, cost structures, and formulary agreements with pharmaceutical companies. Insurers may also assert that their rules are based on clinical guidelines from organizations like the American College of Cardiology or the National Comprehensive Cancer Network. However, the Annals review found minimal alignment with these national standards across the board. Additionally, critics point out that while some variation may be justified, the degree of inconsistency observed—especially for high-evidence treatments—undermines the purported goal of controlling unnecessary care. Some insurers defend their processes as necessary tools to prevent overutilization and contain costs, but physicians counter that the administrative burden often outweighs any savings. As one primary care physician told Reuters Health, “We’re not denying care—we’re just too busy filling out forms to deliver it efficiently.”
How Does This Inconsistency Affect Patients and Providers?
The real-world impact is significant. Clinicians report spending hours each week navigating insurer portals, resubmitting denied claims, and appealing decisions—time that could be spent with patients. Delays in authorization can postpone critical treatments, such as chemotherapy or mental health interventions, leading to worsened outcomes. Patients, meanwhile, are often unaware of prior authorization requirements until a prescription is denied at the pharmacy, creating confusion and frustration. One study cited in the report found that 93% of physicians experienced care delays due to prior authorization, with 34% reporting that it had led to a serious adverse event for a patient. For those with chronic conditions, switching insurers can mean sudden new hurdles for medications they’ve used safely for years. This unpredictability undermines trust in both the insurance system and the healthcare delivery process.
What This Means For You
If you’re a patient, always confirm with your provider and insurer whether a test or medication requires prior authorization—don’t wait until the pharmacy or imaging center says no. For clinicians, staying updated on multiple insurer policies remains a necessity, though professional organizations continue to push for standardization. At a systemic level, this inconsistency strengthens the case for federal or industry-wide reform to align prior authorization rules with clinical evidence, not corporate policy. The goal should be a system that protects patients from unnecessary care without blocking access to what they need.
Could a national standard for prior authorization improve care coordination and reduce burnout among providers? And if such a framework were developed, which body—be it CMS, specialty societies, or a new regulatory entity—should be responsible for maintaining it? These questions remain unresolved, even as the administrative toll on the U.S. healthcare system continues to grow.
Source: MedicalXpress